Biguanide Compositions for Intestinal Targeted Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, obesity, and related metabolic disorders, such as metformin, pose risks due to systemic bioavailability and side effects, particularly in patients with impaired renal function, and existing therapies have limitations in efficacy and safety.
Innovation Solution
Compositions and methods involving biguanide or related heterocyclic compounds, like metformin, are designed to minimize systemic bioavailability by targeted release in specific intestinal regions, using formulations that adapt to the gastrointestinal tract, including enteric coatings and timed release systems, to reduce plasma absorption and enhance therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metformin is administered systemically to treat diabetes and metabolic disorders, then therapeutic effects are achieved, but systemic bioavailability leads to accumulation and lactic acidosis especially in patients with impaired renal function
Solution Approach 1:
The patent segments the administration of biguanide compounds by targeting specific intestinal regions (upper intestine, lower intestine, or both) rather than systemic administration. This spatial segmentation allows the drug to act locally at the site of absorption to modulate hormonal profiles (GLP-1, PYY, oxyntomodulin) without causing systemic accumulation and lactic acidosis, especially in patients with impaired renal function
Solution Approach 2:
The patent applies local quality by delivering biguanide compounds to specific locations in the gastrointestinal tract (duodenum, jejunum, ileum, colon, or rectum) where they can exert therapeutic effects on glucose metabolism and hormonal regulation. This localized delivery ensures the drug acts where needed while minimizing systemic exposure and harmful effects
2Reliability
If conventional diabetes treatments are used to lower blood glucose levels, then glycemic control is improved, but side effects and limited efficacy persist particularly in patients with impaired renal function
Solution Approach 1:
The patent uses hormonal mediators (GLP-1, PYY, oxyntomodulin) as intermediaries to achieve glycemic control. By administering biguanide compounds to the intestine to stimulate endogenous secretion of these hormones, the treatment indirectly lowers blood glucose levels through physiological pathways rather than direct systemic action, reducing side effects while maintaining efficacy
Solution Approach 2:
The patent changes the administration parameter from systemic to localized intestinal delivery. This parameter change transforms the drug's behavior from causing systemic accumulation to exerting localized effects that modulate hormonal secretion, thereby achieving glycemic control with fewer side effects in patients with impaired renal function
Data Source
AI summary
Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.